bullish

The U.S. Executive Order on Its Biotech Industry May Not Materiality Affect Chinese CRO Industry

196 Views15 Sep 2022 01:04
Broker
The U.S. launched new support to its biotech production, aiming to boost biomanufacturing in pharmaceuticals but also in other industries such as agriculture, plastics, and energy.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Quam Securities
Research from Quam Securities
China & Hong KongEquity Bottom-UpThematic (Sector/Industry)
  • The U.S. Executive Order on Its Biotech Industry May Not Materiality Affect Chinese CRO Industry
    15 Sep 2022
x